RF2 Feasibility and preliminary results of the first clinical trial targeting minimal residual disease in patients with homologous recombination proficient (HRP) ovarian cancer

Identifying clinically undetectable minimal residual disease (MRD) after frontline therapy for ovarian cancer has the potential to improve outcomes by uncovering specific therapeutic targets and enabling earlier, more personalized intervention. Clinical trials targeting MRD after frontline therapy, diagnosed by second look laparoscopy (SLL), may offer a clinical benefit of personalizing maintenance therapy. We describe the preliminary results of the first of these trials aimed at determining progression free survival (PFS) of patients with surgically documented MRD treated with bevacizumab until progression.